Abstract

The goal of this study was to determine the frequency of HLA class II antigen expression in colorectal carcinoma (CRC) tumors, its association with the clinical course of the disease, and the underlying mechanism(s). Two tissue microarrays constructed with 220 and 778 CRC tumors were stained with HLA-DR, DQ, and DP antigen–specific monoclonal antibody LGII-612.14, using the immunoperoxidase staining technique. The immunohistochemical staining results were correlated with the clinical course of the disease. The functional role of HLA class II antigens expressed on CRC cells was analyzed by investigating their in vitro interactions with immune cells. HLA class II antigens were expressed in about 25% of the 220 and 21% of the 778 tumors analyzed with an overall frequency of 23%. HLA class II antigens were detected in 19% of colorectal adenomas. Importantly, the percentage of...
stained cells and the staining intensity were significantly lower than those detected in CRC tumors. However, HLA class II antigen staining was weakly detected only in 5.4% of 37 normal mucosa tissues. HLA class II antigen expression was associated with a favorable clinical course of the disease. In vitro stimulation with interferon gamma (IFNγ) induced HLA class II antigen expression on two of the four CRC cell lines tested. HLA class II antigen expression on CRC cells triggered interleukin-1β (IL-1β) production by resting monocytes. HLA class II antigen expression in CRC tumors is a favorable prognostic marker. This association may reflect stimulation of IL-1β production by monocytes.

*Neoplasia* (2014) 16, 31–42

**Introduction**

According to genetic profiles, colorectal carcinoma (CRC) tumors are classified in two groups. About 75% of patients have CRC tumors of sporadic origin, with no clear evidence of having inherited the disease. In contrast, about 25% of patients with CRC tumors are likely to have a hereditary contribution. The cause of an inherited CRC tumor risk involves defects in the DNA mismatched repair (MMR) system leading to an increased possibility of colorectal cells to acquire mutations [1]. MMR deficiency condition seems to be associated with high density of lymphocyte infiltration, reduced invasiveness, and improved survival [2].

Besides being expressed on antigen presenting cells, B lymphocytes, and activated T lymphocytes, HLA class II antigens are also expressed in a variety of malignant tumors of different embryological origin. The frequency of expression reaches 75.4% in medullary breast carcinoma, 17.7% in ductal breast carcinoma [3], 100% in renal cell carcinoma [4], and 60% in primary melanomas [5]. In some malignancies such as melanomas [6] and osteogenic sarcoma [7], HLA class II antigen expression is associated with poor prognosis, while it is associated with favorable prognosis in cervical carcinoma [8] and in squamous cell carcinoma of the larynx [9]. Limited information is available about HLA class II antigen expression in CRC tumors and its clinical significance. To the best of our knowledge, a total of only two large studies involving more than 300 patients have been accomplished so far. The first study included 357 patients with microsatellite stable CRC tumors [10]; the second study involved 1016 CRC patients with rectal carcinoma [11]. The average frequency of HLA class II antigen expression has been found to be 38% with ranges from 21% to 55% [12]. Conflicting information is available about the clinical significance of HLA class II antigen expression in CRC tumors. HLA class II antigen expression in CRC tumors has been reported to be associated with favorable prognosis by Lovig et al., Matsushita et al., and Morita et al. [10,13–15] and in a population of patients with rectal carcinoma by de Bruin et al. [11] but also with irrelevant prognosis because HLA class II antigen expression in CRC cells was not associated with the clinical course of the disease by Moller et al., Mulder et al., Diederichsen et al., and Momburg et al. [16–19]. The reason(s) for these conflicting results is (are) not known.

In human, presence of inflammatory infiltrate, in CRC tumors, has been associated with favorable prognosis [2,20]. HLA class II antigens play a pivotal role in stimulating an inflammatory response against pathogen and tumor antigens. They are not expressed in normal colonic epithelium but could be detected in CRC cells. Furthermore, HLA class II antigen expression in colonic epithelial and CRC cells is inducible on stimulation with interferon gamma (IFNγ) [21]. These data suggest that HLA class II antigen expression in the CRC tumors may result from the activity of pro-inflammatory cytokines and may be associated with immunostimulation.

Information about HLA class II antigen expression in CRC tumors and its clinical significance may contribute to our understanding of the role of these molecules in the interactions of CRC tumors with the host’s immune system and to the design of strategies to modulate these interactions. Therefore, in the present study, we have determined the frequency of HLA class II antigen expression in about 1000 CRC tumors, using two tissue microarrays (TMAs) independently constructed at two medical centers. Furthermore, we have analyzed the association of HLA class II antigen expression in CRC tumors with their histopathologic characteristics and the clinical characteristics of the disease. Lastly, we have investigated the potential role of pro-inflammatory cytokines in the functional properties of HLA class II antigens expressed by CRC cells.

**Materials and Methods**

**Colorectal Specimens and TMAs**

Retrospective materials obtained from formalin-fixed paraffin-embedded biopsies of surgically removed CRC tumors were separately collected and stored in the Institutes of Pathology at the University of Athens (Athens, Greece) and at the biobank of the Institute of Pathology at the University of Basel (Basel, Switzerland). The use of these tissue specimens and data for analysis was approved by the Regional Ethics Committee.

The Athens study comprised 220 nonconsecutive CRC tissue resections. In addition, we included 42 colorectal adenomas and 37 normal colonic mucosa tissues obtained from surgical resections of tumor-free areas adjacent to CRC tumors. The Basel study comprised 1420 unselected nonconsecutive CRC tissue resections [20]. The TMAs were constructed as described elsewhere [22]. However, only 778 CRC tumor punches, also obtained from surgical resection with tumor-free margins, contained ≥80% of malignant cells and, therefore, were suitable for evaluation, while the remaining spots were unavailable because of missing representative CRC tissues (Table 1).

Briefly, formalin-fixed paraffin-embedded tissue blocks of CRC resections were obtained. Tissue cylinders (0.6-mm diameter) were punched from morphologically representative tissue areas of each donor tissue block in a paraffin block recipient by a semiautomated tissue arrayer.
Each punch was made from the center of the tumor such that each TMA spot consisted of at least 50% tumor cells.

**Antibodies**

LGII-612.14 monoclonal antibody (mAb) recognizes monomorphic epitope expression in the β chain of HLA-DR, DQ, and DP antigens. The antibody was prepared and characterized as described [23]. Antibody specificity was validated by immunoprecipitation, ELISA, and binding assay. Peroxidase-labeled secondary antibody was purchased from Dako (Glostrup, Denmark). Fluorescein isothiocyanate–conjugated goat anti-mouse Ig and anti–HLA-DR antibodies were purchased from BD Biosciences (San Jose, CA). Phycoerythrin–conjugated anti–HLA-DR, DQ, DP antibodies were purchased from Abcam (Cambridge, United Kingdom).

**Cell Lines and Peripheral Blood Mononuclear Cells**

COLO205, HCT116, HT29, and SW480 cell lines were cultured in Dulbecco’s modified Eagle’s medium supplemented with heat-inactivated FBS. The identity of the indicated cell lines was monitored by HLA class I and II antigen expression and in vitro growth pattern. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors’ buffy coats of the Policlinico “Tor Vergata” blood bank, using the Ficoll-Hypaque density gradient separation method [24]. PBMCs were cultured in RPMI 1640 medium (Life Technologies Europe, Milan, Italy) supplemented with heat-inactivated FBS, glutamine (2 mM), streptomycin (100 U/ml), and penicillin (100 U/ml); this medium is referred to as the complete medium.

**Immunohistochemistry**

TMAs were stained with a two-step procedure using mAb LGII-612.14 as a primary antibody and a peroxidase-labeled rabbit anti-mouse IgG antibody as a secondary antibody. Following dewaxing and rehydration of the TMA slides, in distilled water, endogenous peroxidase activity was blocked with a 0.5% H₂O₂ solution. Colorectal tissue sections were then incubated with mAb LGII-612.14 for 30 minutes at room temperature. Following three washes with phosphate-buffered saline, tissue sections were incubated with peroxidase-labeled secondary antibody for 30 minutes at room temperature. For antigen visualization, colorectal tissues were soaked for 30 minutes at room temperature in 3-amin-9-ethylcarbazole (Dako) supplemented with substrate-chromogen and counterstained with Gill’s hematoxylin (Dako). CRC punches were evaluated for HLA class II antigen expression by counting the total number of positive cells detected in each tumor punch. HLA class II antigen–positive CRC and inflammatory cells were clearly identified by morphologic evaluation. Results were validated by at least three independent investigators achieving an optimal concordance rate of 90%.

**Quantitative Reverse Transcription–Polymerase Chain Reaction of Gene Expression in Colorectal Tissues**

Following the Basel Internal Review Board (IRB) approval (63/07), freshly obtained specimens from surgically excised CRC, not included in the tumor associated macrophage (TAM) collection, and autologous normal colorectal mucosa samples at a distance from the tumor were submerged in RNAlater (Qiagen, Venlo, The Netherlands) and stored overnight at 4°C. Samples were then frozen at −20°C for long-term storage. Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen) allowing routine purification of high-quality RNA. RNA was then subjected to reverse transcription (RT) using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA). Quantitative RT–polymerase chain reaction (qRT-PCR) was performed using the TaqMan universal PCR master mix (Applied Biosystems, Foster City, CA) and the following primers and probes:

- for IFNγ [25], forward: AGCTCTGCATCGTTTTTGGTT, reverse: GTTCCATTATCGCTACATCTGAA and probe: FAM-TCTTGGCTTATGCAGAC-TAMRA; interferleukin-1β (IL-1β): primers and probes were purchased as a kit (ref. Hs99999929_m1) from Applied Biosystems and used according to the manufacturer’s instructions;
- for IL-6 [26], forward: CAGCCCTGAGAAGGAGCAGAT, reverse: GTTCAGGGTTTCTGCCC and probe: FAM-AGTAACTAGTGAAGCAGAAGCAGCA-TAMRA; for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [26], forward: ATGGGGAAGGTGAAGGTCG, reverse: TAAAG-CAGCCCTGAGAAGGAGCAGAC and probe: FAM-CGCCTATACGGACCAAAATCG-TAMRA.

Gene expression was quantified as already described [27]. Normalization of gene expression was done on the GAPDH housekeeping gene.

**Flow Cytometry**

CRC cells were incubated on ice, for 30 minutes, in the presence of 1 μg per million cells of the HLA class II antigen–specific mAb
Following two washes, cell surface–bound antibodies were detected using fluorescein-conjugated anti-mouse IgG antibodies. Cells were then analyzed using a two-laser BD FACS Calibur equipped with a Cell Quest software package (Beckton-Dickinson, San Jose, CA).

**Magnetic Sorting of Peripheral Blood Monocytes**

Freshly isolated PBMCs (50–70 × 10⁶) were washed twice in modified MACS buffer (phosphate-buffered saline supplemented with 0.5% bovine albumin). Then, 50 to 70 μl (1 μl per 1 million of PBMCs) of anti-CD14 magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) was added to the PBMC pellet. Following a 30-minute incubation on ice, cells were washed twice in modified MACS buffer. Cells were resuspended in 1 ml of modified MACS buffer and passed through a 0.40-μm cell strainer (BD Falcon, San Jose, CA), in a magnetic column. CD14⁺ cells retained in the column were eluted by a strong mechanical pressure. Following two washes, monocytes were resuspended at the concentration of 1 × 10⁶/ml, in complete medium, for functional experiments.

**Cytokine Array**

The amount of cytokines in the supernatant harvested from cultures of COLO205 and PBMCs was assessed, using a duplicate of 42 human cytokine array system (RayBiotech Inc, Norcross, GA), which detects the antibody-cytokine sandwich by chemiluminescence. For cytokine blocking experiments, before PBMCs or monocytes were mixed with COLO205 cells, FcyRs of PBMCs or monocytes were blocked using mouse IgG (6–10 μg/ml) or FcyR blocking solution (Miltenyi Biotec). HLA class II antigen blockade was accomplished by incubating IFNγ (10 ng/ml)–treated COLO205 cells with 3 μg of LGII-612.14 mAb for 30 minutes on ice in 100 μl of complete medium.

**Enzyme-Linked Immunosorbent Assay**

IL-1β and IL-6 levels were measured in the supernatants harvested from the cultures using commercially available IL-1β (BD Biosciences) and IL-6 (R& D Systems, Minneapolis, MN) ELISA kits with a sensitivity of 0.80 and 0.70 pg/ml, respectively. Supernatants harvested from cultures of COLO205 and PBMCs were added, in triplicates, to wells previously coated with anti-IL-1β or anti-IL-6 capture antibodies. Wells were covered with plate sealers, incubated for 2 hours at room temperature, and washed five times with 300 to 400 μl of wash buffer. Following the last wash, plates were blotted on absorbent paper to remove the remaining buffer. Then, 100 μl of biotin-conjugated anti-IL-1β antibody or 200 μl of HRP-conjugated anti-IL-6 antibody was added to each well for 2 hours at room temperature. Following extensive washing, substrates were added, and plates were incubated for 30 minutes at room temperature in the dark. Reactions were stopped by adding 50 μl of stop solution to each well. The absorbance was read at 450 nm within 30 minutes.

**Statistical Analysis**

HLA class II antigen–positive CRC cells were analyzed, in each CRC tumor punch, by counting a maximum number of 100 positive cells. The threshold for this marker was calculated by means of receiver operating characteristic curve analysis in the testing collective of Athens. Punches containing ≤15 and >15 HLA class II antigen–positive CRC cells were scored negative and positive, respectively. The calculated threshold was tested in the collective of Basel. Survival time differences were evaluated using the log-rank test in univariate analysis. Multivariate hazard Cox regression analysis was performed by adjusting for CRC standard prognostic factors including pT, pN, tumor grade, vascular invasion, age, and metastasis. Hazard ratios and 95% confidence intervals were used to calculate the validity of the prognostic effect.

Correlation analysis among biologic markers was assessed using the Spearman rank correlation coefficient.

Statistical analyses were performed using SPlus software (version 6.1; Insightful Corporation, Seattle, WA) and Statistical Analysis System software (SAS Institute, Cary, NC).

## Results

**Association of HLA Class II Antigen Expression with Disease Progression in CRC Tumors**

HLA class II antigens were found to be expressed by CRC cells in about 23% of the tumors tested. Representative staining patterns are shown in Figure 1, which indicates that the majority of CRC cells were stained by mAb LGII-612.14 in the tumors expressing HLA class II antigens (Figure 1A). In contrast, HLA class II antigens were detected in about 95% of inflammatory infiltrating cells of the CRC tumors analyzed. Representative examples are shown in Figure 1, B and C. HLA class II antigens were not detected in cells of normal colorectal mucosa but were found to be expressed by immune cells in the interstitial tissues (Figure 1D).

We next investigated whether HLA class II antigen expression was associated with malignant transformation of colorectal cells. To this end, we compared HLA class II antigen expression in 37 normal colorectal mucosa samples, in 42 colorectal adenomas, and 220 CRC tumors. The frequency of HLA class II antigen expression increased with disease progression because it was about 5% in the normal mucosa samples tested, about 19% in the colorectal adenoma samples tested, and about 25% in the CRC tumors tested. Furthermore, in CRC tumors, the percentage of stained malignant cells and their staining intensity were significantly higher than those found in colorectal adenomas (P < .013) and in normal colorectal mucosa (P < .0001; Table 2). The difference, in HLA class II antigen expression, between normal colorectal mucosa and colorectal adenoma was also significant (P = .01) corroborating the conclusion that in colorectal mucosa HLA class II antigen expression is associated with disease progression.

**Association of HLA Class II Antigen Expression in CRC Cells with Patients’ Prolonged Survival**

To assess the clinical significance of HLA class II antigen expression by CRC cells, we correlated it with the histopathologic characteristics of the lesions and with the clinical characteristics of the patients. For this analysis, patients were divided into the following two groups: those who contained >15 malignant cells, per TMA, stained by mAb LGII-612.14 in their tumor punches and those who contained <15.

The presence of ≤15 CRC cells stained by mAb LGII-612.14 in tumor punches was significantly associated with lymph node involvement (P < .0001), presence of metastasis (P < .0021), and lymphatic invasion (P ≤ .008). Table W1 shows a detailed description of the association of HLA class II antigen expression with tumor stage in the Athens study. There was a significant association.
between low HLA class II antigen–positive CRC cell counts and high tumor stage ($P < .0001$). Similar results were obtained in the larger collective of the Basel study (data not shown). However, there was no association with the histologic characteristics of the tumors, as well as their grade and location. Furthermore, the survival of patients with $\leq 15$ CRC cells stained by mAb LGII-612.14 in their tumor punches was significantly shorter than that of patients with $>15$ malignant cells stained by mAb LGII-612.14 in their tumor punches.

To determine whether HLA class II antigen expression in CRC cells was an independent prognostic marker, we performed a multivariate survival analysis of HLA class II antigen expression in CRC cells and pT, pN, and metastasis. Table W2 shows that HLA class II antigen expression in CRC cells was an independent favorable prognostic factor.

Because the American Society of Clinical Oncology (ASCO) guidelines for the identification of new biologic tumor markers recommend data validation at least by an independent study, we assessed the impact of HLA class II antigen expression on the overall survival (OS) of patients with CRC in an additional group of patients of the Basel study. Of 778 patients with CRC whose tumors were used for immunohistochemical analysis, 742 patients were also available for an OS estimation. Univariate analysis confirmed that patients ($N = 153$) with CRC tumors having $>15$ malignant cells, per tumor punch, stained by mAb LGII-612.14 had a significantly (0.007) longer OS time than patients ($N = 589$) with CRC tumors having $\leq 15$ CRC cells, per tumor punch.

Furthermore, we investigated in 730 patients with CRC of the Basel study the impact of the HLA class II antigen–positive inflammatory cells in the CRC tumors on the OS of patients with CRC. Figure 2C shows that patients ($N = 688$) with CRC tumors having $>6$ HLA class II antigen–positive inflammatory cells, per tumor punch, had a longer OS time than patients ($N = 42$) with CRC tumors having $\leq 6$ HLA class II antigen–positive inflammatory cells per tumor punch. However, the difference did not reach the level of statistical significance ($P = .09$).

We then assessed the relationship between HLA class II antigen expression and the inflammatory infiltrate of the CRC tumors.
Table W3 shows that CRC tumors with HLA class II antigen-positive CRC cells correlated with the presence of CD16+ myeloid and T cell antigens. Conversely, there was no correlation with natural killer (NK)–NK-T and myeloid markers. Tumors rich in HLA class II antigen-positive inflammatory cells maintained a weak but significant correlation with the majority of immune markers indicated in Table W3. These data suggest that there may be a correlation between HLA class II antigen expression and CD16 myeloid and T cell infiltration [20,28,29].

IFNγ, IL-1β, and IL-6 Expression in Freshly Removed CRC Tumors

Because HLA class II antigens are pivotal players of the immune response and their expression can be induced by pro-inflammatory cytokines including IFN-γ, we explored the expression of pro-inflammatory cytokines by qRT-PCR in CRC tumors and normal colorectal mucosa. Among 10 CRC tumors available, 10 were evaluated for IFNγ and IL-1β gene expression and 9 for IL-6 gene expression. CRC tumors contained IFNγ (P = .004), IL-1β (P = .001), and IL-6 (P = .001) gene expression levels significantly higher than those assessed in normal colonic mucosa (Figure 3).

COLO205 Cells and PBMCs Trigger IL-1β and IL-6 Inflammatory Cytokine Production

Because inflammatory cytokines are capable of polarizing macrophage toward M1 phenotype, we investigated whether HLA class II antigen–positive CRC cells in the presence of allogeneic PBMCs could contribute to develop an inflammatory microenvironment in vitro.

Following a 48-hour incubation with IFNγ at 37°C, two of four CRC cell lines including COLO205 and HT29 cells expressed HLA class II antigens (Figure 4). However, IFNγ did not induce CD80, CD86, and CD18 expression (data not shown). These results suggest that HLA class II antigens are heterogeneously expressed among CRC cell lines.

Figure 5A shows that resting PBMCs and COLO205 cells without or with HLA class II antigen expression produced traces of transforming

![Figure 2](image-url)  
**Figure 2.** HLA class II antigen expression is associated with improved OS in CRC of the Athens and Basel studies. (A) Survival probability according to the Athens study: The red line shows OS probability of CRC patients with HLA class II antigen–positive CRC cells; the blue line shows OS of CRC patients with HLA class II antigen–negative CRC cells. (B) Survival probability according to the Basel study: The red line shows OS probability of CRC patients with HLA class II antigen–positive CRC cells; the blue line shows OS probability of CRC patients with HLA class II antigen–negative CRC cells. (C) Survival probability according to the level of infiltration of HLA class II antigen–positive or –negative inflammatory cells. The red line shows OS probability of CRC patients with their CRC tumors infiltrated by HLA class II antigen–positive immune cells; the blue line shows OS probability of CRC patients with their CRC tumors noninfiltrated by HLA class II antigen–positive immune cells. Statistical differences between groups are indicated. The definition of HLA class II antigen–positive or –negative tumors is described in the Materials and Methods section.

![Figure 3](image-url)  
**Figure 3.** Gene expression of the pro-inflammatory cytokines IL-1β, IFNγ, and IL-6 in freshly resected CRC tumors and normal colorectal mucosa. CRC tumors and normal colorectal mucosae (CM) were obtained during surgery and placed in Falcon tubes. Following mechanical separation and DNA digestion, total RNA was isolated from CRC and colorectal tissues and subjected to RT. Then, cDNA was analyzed by qRT-PCR for IL-1β, IFNγ, and IL-6 gene expression as described in the Materials and Methods section. Data are expressed as a ratio to GAPDH housekeeping gene as indicated; solid circles represent normal colorectal mucosa; solid squares represent CRC tumors.
growth factor–β1 (TGF-β1) but did not secrete IL-4 and IL-13. However, supernatants harvested from cultures of COLO205 cells and PBMCs showed changes in M2 cytokine content since there was an increase in the level of IL-13. Furthermore, we noted a reduction of IL-13 production when PBMCs were cultured in the presence of HLA class II antigen–positive COLO205 cells. These results suggest that HLA class II antigen–positive COLO205 cells failed to induce the production of TGF-β1, IL-4, and IL-13 cytokines.

We next investigated whether HLA class II antigen–positive COLO205 cells could affect the production of IL-1β and IL-6.

Following a 48-hour incubation of PBMCs with or without HLA class II antigen–positive or –negative COLO205 cells, supernatants harvested from a culture of PBMCs and HLA class II antigen–positive COLO205 cells showed high contents in IL-1β. In contrast, a lower amount of IL-1β was detected in the supernatants harvested from a culture of PBMCs and HLA class II antigen–negative COLO205 cells (Figure 5B, upper panel). Resting PBMCs and HLA class II antigen–negative or –positive COLO205 cells did not produce IL-6. Conversely, supernatants obtained from a culture of PBMCs and HLA class II antigen–negative COLO205 cells contained levels of IL-6 lower than those detected in the supernatants harvested from a culture of PBMCs and HLA class II antigen–positive COLO205 cells (Figure 5C, upper panel). These results suggest that the production of IL-1β and IL-6 in the supernatants of PBMCs and COLO205 was associated with HLA class II antigen expression on COLO205 cells.

To assess the impact of HLA class II antigens on IL-1β and IL-6 production, PBMCs were cultured in the presence of HLA class II antigen–positive COLO205 cells coated with or without anti–HLA class II antigen mAb. Figure 5B, lower panel, shows that IL-1β production in the cell cultures composed of HLA class II antigen–positive COLO205 cells and PBMCs was inhibited by the HLA class II antigen–specific mAb LGII-612.14, whereas IL-6 production was not (Figure 5C, lower panel). These results strongly suggest that HLA class II antigens played a role in the secretion of IL-1β. Similar results were obtained when IL-1β and IL-6 cytokine production was assessed using an ELISA (Figure 5D).

IL-1β Production Involved Monocytes

Because IL-1β is typically produced by monocyte/macrophage, we assessed whether co-cultures of monocytes and HLA class II antigen–positive COLO205 generated IL-1β. Supernatants harvested from a culture of monocytes and HLA class II antigen–positive COLO205 cells obtained from three healthy donors (Figure 6A) showed the highest content of IL-1β (Figure 6B). Conversely, supernatants harvested from a cell culture consisting of monocytes cultured in the absence of COLO205 cells, or PBMCs, depleted of monocytes, with or without HLA class II antigen–positive COLO205 cells did not produce IL-1β, suggesting that IL-1β production requires the presence of monocytes and HLA class II antigen–positive COLO205 cells.

To identify whether monocytes or HLA class II antigen–positive COLO205 cells secreted IL-1β, we incubated monocytes with HLA class II antigen–negative or –positive COLO205 cells. Subsequently, monocytes were magnetically separated from COLO205 cells, and both cells were placed in a single culture condition. Following a 48-hour incubation, the supernatants harvested from resting monocytes or COLO205 cells negative and positive for HLA class II antigen expression as well as COLO205, previously stimulated with monocytes, did not show significant production of IL-1β. Conversely, monocytes previously stimulated with HLA class II antigen–positive COLO205 cells produced most of the IL-1β detected in the supernatants of the different culture conditions. As expected, lipopolysaccharides (LPS) and IFNγ stimulation of monocytes, which were used as positive controls, induced IL-1β production (Figure 6C). These results suggest that HLA class II antigen–positive COLO205 cells specifically triggered IL-1β by monocytes.

Discussion

In this study, we investigated HLA class II antigen expression in a large collection of about 1000 CRC tumors recruited in two independent European institutions. Immunohistochemical analysis of the CRC tumor showed an overall frequency of HLA class II antigen expression of 23% ranging between 21% of the Basel study and 25% for the Athens study. In contrast, 95% of CRC TMA punches analyzed...
had HLA class II antigen–positive inflammatory cells. Furthermore, when CRC tumors were classified as positive, in most of the cases, the frequency of the CRC positive cells was high, and the intensity of the staining was particularly strong. Our results are in agreement with the study of de Bruin et al. who find an expression frequency of about 21% but are conflicting with Lovig et al. who found a frequency of HLA class II antigen expression of 51% [10]. A possible explanation for this difference may involve the choice of the investigators to consider different cutoff scores to define positive or negative CRC tumors. Our choice to consider the threshold of 15 positive cells was based on information obtained from receiver operating characteristic curve analysis in the collective of Athens and validated in the independent collective of Basel. Alternatively, it could be also possible to speculate that there were different levels of cytokine production in the CRC tumors used in these studies. Finally, HLA class II antigen expression disparity may reflect different molecular profiles of the CRC tumors included in these studies. However, we tend to exclude this hypothesis because, although the Athens study only included MMR-proficient CRC tumors, while the Basel study included 83% and 17% of MMR-proficient and MMR-deficient CRC tumors,

Figure 5. HLA class II antigen expression on CRC cells regulated IL-1β production in the cell cultures composed of COLO205 cells and PBMCs. COLO205 CRC cells were cultured in the presence or absence of IFNγ (10 ng/ml) for 48 hours in complete medium. HLA class II antigen expression on COLO205 cells was confirmed by flow cytometry. After extensive washes, COLO205 cells and freshly isolated PBMCs were co-cultured, in the absence of IFNγ, for 48 hours at 1:4 ratios, respectively, according to the indicated experimental conditions. Following a 48-hour incubation, supernatants were evaluated in duplicates for the presence of TGF-1β, IL-4, IL-13 (A), IL-1β (B, upper panel), and IL-6 (C, upper panel) cytokines using a cytokine array. HLA class II antigen–positive COLO205 cells were cultured in the presence or absence of blocking anti–HLA class II antigen mAbs (6 μg/ml) for 30 minutes at 4°C. Then, cells were washed and cultured in the presence of freshly isolated PBMCs whose FcγRs were previously blocked using mouse IgG. Following a 48-hour incubation, supernatants were harvested and analyzed in duplicates for IL-1β (B, lower panel) and IL-6 (C, lower panel) contents. Triplicates of 100 μl of supernatants obtained after 30 hours of culture condition indicated in the x-axis were analyzed for IL-1β (D, upper panel) and IL-6 (D, lower panel) protein content by ELISA. In all situations, where blocking conditions were performed, COLO205 cells were pre-coated with the anti–HLA class II antigen mAb LGII-612.14, while PBMC FcγRs were blocked using a commercially available blocking buffer (Miltenyi, Bologna, Italy). Cytokine protein spots were analyzed by photo densitometry and expressed as OD relative units calculated as follows: cytokine spots OD/standard control spots OD × 100. Abbreviations: II, HLA class II antigen–positive; a-II ag, anti–HLA class II antigen mAb LGII-612.14; mono, monocytes.
respectively, no significant differences in HLA class II antigen expression were observed between the groups. In agreement with the studies of Lovig et al. and de Bruin et al., we found that HLA class II antigen expression in the CRC tumor cells was a favorable prognostic factor. However, these results are not in agreement with other studies that suggest HLA class II antigen expression is at least an indifferent prognostic factor without being associated with a favorable clinical course of the disease [16–18]. Explanation(s) for these conflicting results is (are) not known. The existence of such a conflicting situation prompted us the idea that HLA class II antigen expression in the CRC tumor could be significant but not sufficient to generate a tumor microenvironment predisposing to a favorable clinical course of the disease. Then, other factors such as local cytokine production and or type and function of inflammatory immune cells may be involved in such a process.

The expression of HLA class II antigens could be a result of the activation of an inflammatory response mediated by immune cells infiltrating the tumor microenvironment [2,20,30–36]. CRC tumors for a variety of reasons including their microenvironment, rich in bacterial flora, undergo active infiltration of inflammatory cells composed of T lymphocytes and TAMs but limited in NK cells [32]. Thus, the expression of HLA class II antigens is likely to be due to IFNγ producing immune cells during the inflammation process. Indeed, we have found that IFNγ gene expression was upregulated in the CRC tumor microenvironment. Furthermore, in agreement with published results [37], IFNγ triggered HLA class II antigen expression on the cell surface of 50% of CRC cell lines used, including COLO205 and HT29 cells. Because CRC tumor microenvironment is hardly infiltrated by NK cells and rich in T lymphocytes, it is likely to predict that CD4-positive lymphocytes are responsible for the local production of IFNγ.

HLA class II antigen expression in CRC cells, in the presence of IFNγ, is controlled by the methylation of class II transactivator–isoform-PIV (PIV) and is inhibited by somatic mutation of the RFX5 gene [21]. Although, we have not tested our CRC cell lines for FRX5 mutation, we also found that HLA class II antigen expression...
requires the presence of class II transactivator–PIV (data not shown). These results suggest possible mechanisms controlling HLA class II antigen expression in CRC cells on stimulation with IFNγ.

There is an increased consensus supporting the positive effect of a strong inflammatory response, in the CRC tumors, on the OS of patients with CRC [38]. Interestingly, the favorable contribution of TAM infiltration to the clinical course of the patients with CRC makes this disease a compelling exception among solid malignancies investigated so far [20,29,39–42]. Thus, HLA class II antigen expression in the CRC tumors could play a role in countering CRC progression. This situation raises questions about mechanisms by which HLA class II antigen expression in CRC cells protects the host against the tumor.

In this context, we suggest that HLA class II antigen expression in CRC may cause an immunologic antitumor response [20,29,31]. HLA class II antigen expression on CRC cells could activate CD4+ T cells by presenting tumor-associated antigens (TAA). Indeed, a certain number of TAA have been described in CRC [43–48]. However, HLA class II antigen expression is not sufficient to develop a successful CD4+ T cell stimulation because it requires the expression of co-stimulatory molecules on tumor cells [49].

Accordingly, in the allogeneic setting, IFNγ induced HLA class II antigen expression but failed to generate B7, B7.1, and CD18 expression on COLO205 cells. As a consequence, we failed to produce a CD4+ T cell proliferation (data not shown). However, HLA class II antigen expression on COLO205 cells induced the production of pro-inflammatory cytokines including IL-1α and IL-6 by monocytes but failed to generate anti-inflammatory cytokines including TGF-β, IL-13, and IL-4.

IL-1β is a pro-inflammatory cytokine, and the expression of the IL-1β receptor is required for an efficient activation of dendritic cells (DC). Furthermore, IL-1p induces macrophage recruitment and macrophage auto-stimulation [50] shaping a pro-inflammatory microenvironment with a potential anti-tumor activity [20,29,33].

IL-1β and IL-6 molecules are pro-inflammatory cytokines mainly produced by granulocyte/monocytes [51,52]. IL-6 molecule promotes the transition from acute to chronic phase of inflammation reducing granulocyte trafficking and increasing monocyte recruitment at the damaged tissues [52]. Thus, a pro-inflammatory infiltrate is likely to have a positive clinicopathologic effect on the clinical course of human CRC tumors. However, these results are not in agreement with mouse models of CRC because inflammation has been found to be involved in the pathogenesis of colitis-associated cancer. According to these studies, in the tumor microenvironment, IL-6 secreted by bone marrow–derived myeloid cells activates signal transducer and activator of transcription 3 (STAT3) signaling pathways leading to the concentration of β-catenin into the nuclei favoring tumor progression. In addition, IL-1β can also induce IL-6 production promoting colitis-associated cancer progression [53].

Thus, in human and mouse, inflammation is differently linked to CRC tumors. There is evidence that inflammation is connected to cancer intrinsic and extrinsic pathways. The intrinsic pathway is activated by genetic modifications leading to inflammation and cancer. The extrinsic pathway involves CRC tumors growing in a tumor microenvironment with a preexistence of inflammatory condition such as ulcerative colitis and Chron’s disease [54]. Most of the CRC tumors evaluated rose in mice with inflammatory bowel diseases, while the majority of our patients had no underlying inflammatory conditions. These differences may explain the conflicting results obtained in human and mouse studies. Then, inflammation developing in CRC tumors derived from genetic alteration may have protective activity. In contrast, inflammation of CRC tumors derived from colorectal mucosa chronically affected by inflammatory diseases may generate a qualitative different inflammation that may promote cancer progression. However, ulcerative colitis and Chron’s disease are often associated with immune dysregulation. The idea that inflammation could be good and bad in CRC tumors is also reinforced by Klintrup et al. [38]. These investigators found that inflammatory cell infiltration at the invasive margin, in CRC, was a favorable prognostic factor, while Richards et al. showed that systemic inflammation was a poor prognostic marker in patients with CRC [55].

In human, certain HLA-DR genotype alleles have been associated with ulcerative colitis [56]. It is tempting to speculate that aberrant expression of HLA class II antigens may differentially affect the pathogenesis of malignant and autoimmune diseases having a protective role in CRC but a detrimental one in autoimmune diseases [57]. However, aberrant expression of HLA class II antigens worsened the clinical outcome of thyroiditis, type I diabetes, and biliary cirrhosis [58–60].

According to our study, HLA class II antigen–positive cells induced IL-1β production in peripheral blood monocytes. We and others have shown that CRC tumor is rich in TAMs. Phenotypic analysis of freshly infiltrating cells indicates two types of TAMs: The first is CD16 positive, while the second is CD16 negative. CD16-positive TAMs are CD11c high and are associated with survival. Thus, It is possible to speculate that these cells could be a target of IL-1β in the context of CRC tumors perhaps favoring DC differentiation.

Considering that HLA class II antigen expression may be induced in the presence of IFNγ, it could be possible to use this cytokine as a platform for developing personalized immunotherapeutic studies. To avoid the adverse effect and the nonspecific stimulation of IFNγ on the immune system, we may think to deliver IFNγ into the CRC tumors using anti–TAA–IFNγ fusion proteins. However, Trinh et al. have demonstrated that is possible to deliver IFNβ to human lymphoma using an anti–CD10–IL-1β fusion protein [61].

References


of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 100, 3398–3403.


Table W1. Association of HLA Class II Antigen Expression and Tumor-Node-Metastasis Stage.

<table>
<thead>
<tr>
<th>Stage</th>
<th>HLA Class II Antigens N (%)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>I</td>
<td>23 (16.6)</td>
<td>22 (31.0)</td>
</tr>
<tr>
<td>II</td>
<td>29 (20.9)</td>
<td>27 (38.0)</td>
</tr>
<tr>
<td>III</td>
<td>66 (47.5)</td>
<td>21 (29.6)</td>
</tr>
<tr>
<td>IV</td>
<td>21 (15.1)</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Total</td>
<td>139</td>
<td>71</td>
</tr>
</tbody>
</table>

CRC tumor punches were screened for HLA class II antigen expression. CRC tumors were considered HLA class II positive low when the total count of HLA class II positive CRC cells was ≤15 and high when it was >15.

Table W2. Multivariate Survival Time Analysis of HLA Class II Antigen Expression with pT, pN, and Metastasis.

<table>
<thead>
<tr>
<th>Feature</th>
<th>P Value</th>
<th>Hazard Ratio (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA class II</td>
<td>.0075</td>
<td>0.43 (0.24-0.8)</td>
</tr>
<tr>
<td>pT stage</td>
<td>.2746</td>
<td>1.55 (0.71-3.42)</td>
</tr>
<tr>
<td>pN stage</td>
<td>.0028</td>
<td>2.44 (1.36-4.37)</td>
</tr>
<tr>
<td>Metastasis</td>
<td>&lt;.0001</td>
<td>3.53 (2.0-6.2)</td>
</tr>
</tbody>
</table>

Table W3. Spearman Rank Correlation Coefficients between HLA Class II Antigen and Biologic Antigen Expression in the CRC Tumors.

<table>
<thead>
<tr>
<th>Feature*</th>
<th>CRC Class II Ags</th>
<th>Infiltrate Class II Ags</th>
<th>CD16</th>
<th>CD56</th>
<th>CD57</th>
<th>CD68</th>
<th>CD3</th>
<th>CD4 Peri-T</th>
<th>CD8</th>
<th>Granzyme Intra-T</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRC HLA class II Ags</td>
<td>1</td>
<td>–</td>
<td><strong>0.20</strong></td>
<td>0.04</td>
<td>0.07</td>
<td>0.1</td>
<td><strong>0.19</strong></td>
<td>0.05</td>
<td>0.29</td>
<td>0.25</td>
</tr>
<tr>
<td>Infiltrate HLA class II Ags</td>
<td><strong>0.18</strong></td>
<td>1</td>
<td><strong>0.29</strong></td>
<td>0.16*</td>
<td><strong>0.20</strong></td>
<td><strong>0.24</strong></td>
<td><strong>0.26</strong></td>
<td>0.11</td>
<td><strong>0.16</strong></td>
<td><strong>0.15</strong></td>
</tr>
</tbody>
</table>

*Bolded* correlation coefficient (r) numbers are significant and have P values < .001.
All comparisons were performed with more than 420 paired values.
All correlation are positive and weak though significant.

*P = .003.